COMPARISON OF THE CARDIOTOXICITY OF ABIRATERONE AND ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER USING REAL-WORLD DATA

被引：0
|
作者：
Hu, Jason
Aprikian, Armen
Vanhuyse, Marie
Dragomir, Alice
机构：
来源：
JOURNAL OF UROLOGY | 2021年 / 206卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP24-18
引用
收藏
页码：E418 / E419
页数：2
相关论文
共 50 条
  • [21] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Schmid, Sebastian Christoph
    Geith, Alexander
    Boeker, Alena
    Tauber, Robert
    Seitz, Anna Katharina
    Kuczyk, Markus
    von Klot, Christoph
    Gschwend, Juergen Erich
    Merseburger, Axel Stuart
    Retz, Margitta
    ADVANCES IN THERAPY, 2014, 31 (02) : 234 - 241
  • [22] Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sebastian Christoph Schmid
    Alexander Geith
    Alena Böker
    Robert Tauber
    Anna Katharina Seitz
    Markus Kuczyk
    Christoph von Klot
    Jürgen Erich Gschwend
    Axel Stuart Merseburger
    Margitta Retz
    Advances in Therapy, 2014, 31 : 234 - 241
  • [23] Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis
    M. Koninckx
    J. L. Marco
    I. Pérez
    M. T. Faus
    V. Alcolea
    F. Gómez
    Clinical and Translational Oncology, 2019, 21 : 314 - 323
  • [24] Effectiveness, safety and cost of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world data analysis
    Koninckx, M.
    Marco, J. L.
    Perez, I.
    Faus, M. T.
    Alcolea, V.
    Gomez, F.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (03): : 314 - 323
  • [25] Abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer: a real-world retrospective study in China
    Liu, Min
    Yan, Jiaqing
    Le, Kaidi
    Li, Ying
    Xing, Nianzeng
    Li, Guohui
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [26] Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patients
    Miyoshi, Yasuhide
    Yasui, Masato
    Ttsutsumi, Sohgo
    Kawahara, Takashi
    Uemura, Ko-ichi
    Hayashi, Naruhiko
    Nozawa, Masahiro
    Yoshimura, Kazuhiro
    Uemura, Hiroji
    Uemura, Hirotsugu
    BJUI COMPASS, 2021, 2 (01): : 31 - 38
  • [27] Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?
    Garcia Trevijano Cabetas, Macarena
    Escario-Gomez, Miguel
    Gonzalez-Del Valle, Luis
    Sobrino Jimenez, Carmen
    Bilbao Gomez-Martino, Cristina
    Romero-Garrido, Jose Antonio
    Benedi-Gonzalez, Juana
    Espinosa Arranz, Enrique
    Diaz Almiron, Mariana
    Herrero Ambrosio, Alicia
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2023, 30 (05) : 268 - 272
  • [28] Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
    George, Daniel J.
    Ramaswamy, Krishnan
    Yang, Hongbo
    Liu, Qing
    Zhang, Adina
    Greatsinger, Alexandra
    Ivanova, Jasmina
    Thompson, Betty
    Emir, Birol
    Hong, Agnes
    Freedland, Stephen J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 27 (04) : 756 - 764
  • [29] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Troncoso, Patricia
    Hoang, Anh
    Corn, Paul
    Prokhorova, Ina
    Araujo, John
    Dmuchowski, Carl
    Melhem-Bertrandt, Amal
    Patil, Shiva
    Logothetis, Christopher J.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
  • [30] Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
    Becker, Daniel J.
    Iyengar, Arjun D.
    Punekar, Salman R.
    Ng, Jason
    Zaman, Anika
    Loeb, Stacy
    Becker, Kevin D.
    Makarov, Danil
    ANTICANCER RESEARCH, 2019, 39 (05) : 2467 - 2473
12345